<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849783</url>
  </required_header>
  <id_info>
    <org_study_id>201208775</org_study_id>
    <secondary_id>10120146</secondary_id>
    <secondary_id>P30CA086862</secondary_id>
    <secondary_id>NCI-2013-00883</secondary_id>
    <nct_id>NCT01849783</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma</brief_title>
  <official_title>Single Autologous Transplant Followed by Consolidation and Maintenance for Participants â‰¥ 65 Years of Age Diagnosed With Multiple Myeloma or a Related Plasma Cell Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Margarida Magalhaes-Silverman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial investigates whether patients greater than or equal to 65 years of age&#xD;
      diagnosed with myeloma or another plasma cell malignancy will have better outcomes with&#xD;
      transplant followed by maintenance therapy, as primarily measured by progression-free&#xD;
      survival, versus non-transplant approaches.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the progression-free survival (PFS) from the start of dexamethasone,&#xD;
      cisplatin, Adriamycin (doxorubicin),Cytoxan (cyclophosphamide), etoposide (DPACE) for all&#xD;
      participants who have had at least one day of protocol treatment.&#xD;
&#xD;
      II. To evaluate how well such therapy is tolerated in patients mainly over the age of 65&#xD;
      years by assessing severe complications (intensive care unit [ICU] admission, death) and the&#xD;
      percentage of participants able to complete the full course of therapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate Quality-Of-Life post-transplant using the European Organization for Research&#xD;
      and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30 and QLC-MY20.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      INDUCTION THERAPY: Patients receive dexamethasone orally (PO) on days 1-4 and 8-11, cisplatin&#xD;
      intravenously (IV) continuously, doxorubicin hydrochloride IV continuously, cyclophosphamide&#xD;
      IV, and etoposide IV on days 1-4. Patients then receive pegfilgrastim subcutaneously (SQ) on&#xD;
      days 6 and 13 and undergo collection of stem cells when white blood cell (WBC) and cluster of&#xD;
      differentiation (CD)34 counts are within program range. Following stem cell collection,&#xD;
      patients may receive interim dexamethasone PO on days 1-4, every 14 days at the discretion of&#xD;
      the treating physician.&#xD;
&#xD;
      TRANSPLANT: Beginning between 4 weeks to 6 months after the first day of induction therapy,&#xD;
      patients receive as transplant conditioning regimen dexamethasone PO on days -4 to -1 and&#xD;
      days +2 through +5, bortezomib IV bolus on days -4, -1, 2, and 5, thalidomide PO on days -4&#xD;
      to 5, and melphalan IV on days -4 and -1. Patients undergo autologous peripheral blood stem&#xD;
      cell transplant (PBSCT) on day 0. Between transplant and consolidation therapy, patients&#xD;
      receive dexamethasone PO on days 1-4 every 21 days and thalidomide PO daily.&#xD;
&#xD;
      CONSOLIDATION THERAPY: If administered, post-transplant consolidation may begin 4-6 weeks&#xD;
      after transplant but should occur no more than 4 months later. Most patients will not receive&#xD;
      consolidation. Those that do will receive dexamethasone PO on days 1-4 and 8-11, thalidomide&#xD;
      PO on days 1-11, bortezomib IV on days 1, 4, 8, and 11, cisplatin IV continuously,&#xD;
      doxorubicin hydrochloride IV continuously, cyclophosphamide IV continuously, and etoposide IV&#xD;
      continuously on days 1-4.&#xD;
&#xD;
      MAINTENANCE THERAPY YEAR 1: Beginning 6 weeks-6 months after consolidation therapy or 4 weeks&#xD;
      to 6 months after transplant if consolidation is skipped, patients receive bortezomib IV&#xD;
      bolus on days 1, 4, 15, and 18, thalidomide PO QD on days 1-28, and dexamethasone PO on days&#xD;
      1-4 and 15-18. Treatment repeats every 28 days for up to 12 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      MAINTENANCE THERAPY YEAR 2: Patients receive bortezomib IV on days 1, 4, 15, and 18,&#xD;
      cyclophosphamide PO or IV on days 1 and 15, and dexamethasone PO QD on days 1, 8, 15, and 22.&#xD;
      Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at least once annually at the&#xD;
      study center, but serum for MM marker results will be sent to the study site for close&#xD;
      monitoring of PFS .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal Investgator leaving institution&#xD;
  </why_stopped>
  <start_date type="Actual">April 4, 2013</start_date>
  <completion_date type="Actual">September 24, 2020</completion_date>
  <primary_completion_date type="Actual">September 24, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Progression Free Survival (PFS)</measure>
    <time_frame>From the start of DPACE for all participants who have had at least one day of protocol treatment, assessed up to 4 years</time_frame>
    <description>Estimated with the method of Kaplan-Meier and modeled as functions of clinicopathological factors with Cox regression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine treatment related severe complications and toxicities</measure>
    <time_frame>From the start of DPACE for all participants who have had at least one day of protocol treatment, assessed up to 4 years</time_frame>
    <description>Severe complications defined at ICU admission and death, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0&#xD;
Frequencies of toxicities will be tabulated on all participants. Toxicities will be compared descriptively to historical controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Quality-Of-Life indicators post-transplant</measure>
    <time_frame>Once per year, for 3 years, post-transplant</time_frame>
    <description>Measured using the European Organization for Research (EORTC) Quality of Life Core Questionnaire QLQ-C30 and QLC-MY20</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Extramedullary Plasmacytoma</condition>
  <condition>Isolated Plasmacytoma of Bone</condition>
  <condition>Light Chain Deposition Disease</condition>
  <condition>Primary Systemic Amyloidosis</condition>
  <condition>Stage I Multiple Myeloma</condition>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>autologous stem cell transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction : DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.&#xD;
After collection, participants will receive dexamethasone x 4 days every 14 days.&#xD;
Transplant: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.&#xD;
Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.&#xD;
Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide)&#xD;
Maintenance: Year 1 - VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>autologous stem cell transplant</arm_group_label>
    <other_name>Aeroseb-Dex</other_name>
    <other_name>Decaderm</other_name>
    <other_name>Decadron</other_name>
    <other_name>DM</other_name>
    <other_name>DXM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>autologous stem cell transplant</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>autologous stem cell transplant</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>autologous stem cell transplant</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>autologous stem cell transplant</arm_group_label>
    <other_name>EPEG</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>autologous stem cell transplant</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>autologous stem cell transplant</arm_group_label>
    <other_name>Kevadon</other_name>
    <other_name>Synovir</other_name>
    <other_name>THAL</other_name>
    <other_name>Thalomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>autologous stem cell transplant</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous stem cell transplant</intervention_name>
    <arm_group_label>autologous stem cell transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have had a diagnosis of symptomatic multiple myeloma (MM), MM +&#xD;
             amyloidosis, or POEMS (osteosclerotic myeloma: polyneuropathy, organomegaly,&#xD;
             endocrinopathy, monoclonal protein, skin changes) requiring treatment; participants&#xD;
             with a previous history of smoldering myeloma will be eligible if there is evidence of&#xD;
             progressive disease requiring chemotherapy; Note that study participants do not need&#xD;
             to have active disease at the time of study entry, as participants may have received&#xD;
             up to 12 months of prior chemotherapy, which might have induced a response&#xD;
&#xD;
          -  Protein criteria must be present at diagnosis (quantifiable M-component of IgG, IgA,&#xD;
             IgD, or IgE and/or urinary kappa or lambda light chain, Bence-Jones protein, or Free&#xD;
             Kappa Light Chain or Free Lambda Light Chain) in order to evaluate response.&#xD;
             Non-secretory participants are eligible provided the participant has &gt; 20%&#xD;
             plasmacytosis OR multiple (â‰¥3) plasmacytomas or lesions on MRI at the time of&#xD;
             diagnosis or study enrollment , OR the presence of lesions on PET/CT scan or skeletal&#xD;
             survey at diagnosis or study enrollment.&#xD;
&#xD;
          -  Participants must have received â‰¤12 months of prior chemotherapy for this disease&#xD;
             without evidence of progressive disease with treatment. Participants may have received&#xD;
             prior radiotherapy provided approval has been obtained from the PI. Participants with&#xD;
             a history of radiation who have a platelet count &lt;150,000 due to radiation (disease,&#xD;
             chemo, and other factors have been ruled out) will be excluded from this study.&#xD;
&#xD;
          -  Participants must not have had a prior transplant&#xD;
&#xD;
          -  Participants must be 65-85 years of age at the time of study entry.&#xD;
&#xD;
          -  Ejection fraction by echocardiogram (ECHO) or multigated acquisition scan (MUGA) of &gt;=&#xD;
             40% performed&#xD;
&#xD;
          -  Participants must have adequate pulmonary function studies (PFTs), &gt;= 50% of predicted&#xD;
             on mechanical aspects (forced expiratory volume in 1 second [FEV^1}, forced vital&#xD;
             capacity [FVC]) and diffusion capacity (diffusion capacity of the lung for carbon&#xD;
             monoxide [DLCO]) &gt;= 50% of predicted (adjusted for hemoglobin); if the participant is&#xD;
             unable to complete pulmonary function tests (PFTs) due to disease-related pain or&#xD;
             other circumstances that make it difficult to reliably perform PFTs, documentation of&#xD;
             pulmonary function adequate for transplant will occur via a CT scan without evidence&#xD;
             of major pulmonary disease, and arterial blood gas results&#xD;
&#xD;
          -  Participants must have a creatinine &lt; 3 mg/dl and a GFR &gt;30mL/min/1.73m2&#xD;
&#xD;
          -  Participants must have a performance status of 0-2 based on Eastern Cooperative&#xD;
             Oncology Group (ECOG) criteria; participants with a poor performance status (3-4)&#xD;
             based solely on bone pain will be eligible, provided there is documentation to verify&#xD;
             this&#xD;
&#xD;
          -  Participants must sign the most current institutional review board (IRB)-approved&#xD;
             study (informed consent form) ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior autologous or allogeneic transplant&#xD;
&#xD;
          -  Progressive disease on prior treatment&#xD;
&#xD;
          -  Platelet count &lt; 30 x 10^9/L, unless myeloma-related; if MM-related (hypercellular&#xD;
             marrow biopsy of &gt; 80% and packed with at least 80% plasma cells) the enrolling&#xD;
             investigator must document this&#xD;
&#xD;
          -  &gt; Grade 3 neuropathy&#xD;
&#xD;
          -  Known hypersensitivity to bortezomib, boron, or mannitol&#xD;
&#xD;
          -  Uncontrolled diabetes on appropriate therapy&#xD;
&#xD;
          -  Recent (=&lt; 6 months) myocardial infarction, unstable angina, difficult to control&#xD;
             congestive heart failure, uncontrolled hypertension on appropriate therapy, or&#xD;
             difficult-to-control cardiac arrhythmias&#xD;
&#xD;
          -  Participants must not have a creatinine &gt;3 mg/dl or a GFR &lt;30mL/min/1.73m2.&#xD;
&#xD;
          -  Participants must not have a concurrent malignancy unless it can be adequately treated&#xD;
             by non-chemotherapeutic intervention; participants may have a history of prior&#xD;
             malignancy, provided that he/she has not had any chemotherapy within 365 days of study&#xD;
             entry AND that life expectancy exceeds 5 years at the time of study entry&#xD;
&#xD;
          -  Participants must not have life-threatening co-morbidities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margarida Magalhaes-Silverman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Margarida Magalhaes-Silverman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT01849783/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT01849783/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

